Ironwood Pharmaceuticals Inc. Overview

Ironwood Pharmaceuticals, Inc., a company based in Boston, Massachusetts, operates within the health care sector, specifically in the biotechnology industry. The company is engaged in the discovery, development, manufacturing, and commercialization of pharmaceuticals aimed at treating a range of conditions, including cholesterol, gastrointestinal, cardiovascular diseases, pain, and inflammation.

Financial Snapshot

As of August 13, 2025, Ironwood Pharmaceuticals’ stock closed at $1.07 on the Nasdaq exchange. The company’s market capitalization stands at approximately $123.63 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $5.21 on August 28, 2024, and a 52-week low of $0.53 on May 15, 2025. The price-to-earnings ratio is currently at -5.281, indicating that the company is not yet profitable.

Company Focus

Ironwood Pharmaceuticals is dedicated to advancing treatments for various medical conditions. Their portfolio includes drugs targeting cholesterol management, gastrointestinal disorders, cardiovascular health, and pain and inflammation relief. For more detailed information about their products and initiatives, interested parties can visit their official website at www.ironwoodpharma.com .

Market Presence

The company’s shares are publicly traded on the Nasdaq stock exchange, reflecting its status as a publicly held entity within the biotechnology sector. Despite recent financial challenges, Ironwood Pharmaceuticals continues to focus on its core mission of developing innovative pharmaceutical solutions.

This article provides a concise overview of Ironwood Pharmaceuticals Inc., highlighting its industry focus, financial status, and market presence as of August 2025.